MarketCap
Facebook
X
TelegramQuarterly report 2023-Q3
added 12-12-2023
Akumin Operating Expenses 2011-2026 | AKU
Annual Operating Expenses Akumin
| 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 778 M | 407 M | 22.5 M | 31.8 M | 16.4 M | 11.3 M | 7.71 M | 6.4 M | - | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 778 M | 6.4 M | 160 M |
Quarterly Operating Expenses Akumin
| 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 223 M | 249 M | 185 M | - | 195 M | 195 M | 183 M | - | 103 M | 63.1 M | 60.1 M | - | 59.6 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 249 M | 59.6 M | 152 M |
Operating Expenses of other stocks in the Diagnostics research industry
| Issuer | Operating Expenses | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Burning Rock Biotech Limited
BNR
|
726 M | $ 16.56 | -0.53 % | $ 176 M |  China |
|
Centogene N.V.
CNTG
|
58 M | - | -6.23 % | $ 30.6 M |  Germany |
 |
Agilent Technologies
A
|
1.99 B | $ 111.98 | -2.52 % | $ 34 B |  USA |
 |
Castle Biosciences
CSTL
|
59.5 M | $ 23.85 | -3.44 % | $ 662 M | USA |
 |
Accelerate Diagnostics
AXDX
|
77.2 M | - | -61.36 % | $ 2.46 M | USA |
 |
Aspira Women's Health
AWH
|
13.8 M | - | -6.19 % | $ 10.5 M | USA |
 |
Biocept
BIOC
|
21.6 M | - | -13.05 % | $ 7.29 M | USA |
 |
Chembio Diagnostics
CEMI
|
28.5 M | - | 0.22 % | $ 16.8 M | USA |
 |
Check-Cap Ltd.
CHEK
|
14.1 M | - | - | $ 9.42 M |  Israel |
 |
Co-Diagnostics
CODX
|
50.6 M | $ 1.58 | -3.07 % | $ 2.1 M | USA |
 |
CareDx, Inc
CDNA
|
411 M | $ 19.06 | -13.03 % | $ 1.02 B | USA |
 |
Oxford Immunotec Global PLC
OXFD
|
59.4 M | - | - | $ 562 M |  Britain |
 |
DermTech
DMTK
|
104 M | - | -11.32 % | $ 2.94 M | USA |
 |
Enzo Biochem
ENZ
|
47.4 M | - | -8.98 % | $ 14.8 K | USA |
 |
Exact Sciences Corporation
EXAS
|
2.47 B | - | - | $ 19.8 B | USA |
 |
Fulgent Genetics
FLGT
|
181 M | $ 14.88 | -2.75 % | $ 450 M | USA |
 |
Illumina
ILMN
|
3.69 B | $ 122.08 | -3.81 % | $ 19.4 B | USA |
 |
Global Cord Blood Corporation
CO
|
451 M | - | - | $ 399 M | China |
 |
Fluidigm Corporation
FLDM
|
134 M | - | 1.08 % | $ 308 M | USA |
 |
Genetic Technologies Limited
GENE
|
5.91 M | - | - | $ 7.1 B |  Australia |
 |
Genetron Holdings Limited
GTH
|
983 M | - | 0.12 % | $ 80.1 M | China |
 |
Charles River Laboratories International
CRL
|
607 M | $ 165.0 | -1.03 % | $ 8.18 B | USA |
 |
PRA Health Sciences, Inc.
PRAH
|
585 M | - | - | $ 10.7 B | USA |
 |
HTG Molecular Diagnostics
HTGM
|
24.1 M | - | -20.0 % | $ 1.06 M | USA |
 |
Guardant Health
GH
|
226 M | $ 81.02 | -2.53 % | $ 10.2 B | USA |
 |
Neogen Corporation
NEOG
|
1.48 B | $ 9.09 | -2.73 % | $ 1.97 B | USA |
 |
Lantheus Holdings
LNTH
|
123 M | $ 81.41 | -2.56 % | $ 5.49 B | USA |
 |
Koninklijke Philips N.V.
PHG
|
7.12 B | $ 25.81 | -4.9 % | $ 20 B |  Niderland |
 |
Heska Corporation
HSKA
|
131 M | - | - | $ 1.31 B | USA |
 |
Interpace Biosciences
IDXG
|
20 M | $ 1.99 | 2.9 % | $ 8.8 M | USA |
 |
Personalis
PSNL
|
44.5 M | $ 5.14 | -6.55 % | $ 305 M | USA |
 |
Senseonics Holdings
SENS
|
61.8 M | $ 6.63 | -7.66 % | $ 277 M | USA |
 |
QIAGEN N.V.
QGEN
|
821 M | - | - | $ 10.6 B | Niderland |
 |
Medpace Holdings
MEDP
|
118 M | $ 415.3 | 1.35 % | $ 12 B | USA |
 |
Trinity Biotech plc
TRIB
|
28.3 M | $ 0.6 | -1.75 % | $ 61.9 M |  Irlanda |
 |
Biomerica
BMRA
|
5.64 M | $ 2.16 | -1.22 % | $ 4.96 M | USA |
 |
Motus GI Holdings
MOTS
|
18.6 M | - | -34.28 % | $ 263 K | Israel |
 |
ICON Public Limited Company
ICLR
|
408 M | $ 116.43 | 13.6 % | $ 9.6 B | Irlanda |
 |
Twist Bioscience Corporation
TWST
|
116 M | $ 56.64 | -4.24 % | $ 3.39 B | USA |
 |
Laboratory Corporation of America Holdings
LH
|
1.87 B | $ 255.44 | -1.58 % | $ 21.3 B | USA |
 |
NeoGenomics
NEO
|
430 M | $ 8.59 | -4.77 % | $ 1.1 B | USA |
 |
Celcuity
CELC
|
172 M | $ 118.0 | -1.72 % | $ 5.52 B | USA |
 |
National Research Corporation
NRC
|
38.5 M | $ 15.91 | -5.55 % | $ 356 M | USA |
 |
Myriad Genetics
MYGN
|
964 M | $ 4.62 | -4.65 % | $ 428 M | USA |
 |
Natera
NTRA
|
258 M | $ 194.36 | -2.9 % | $ 19.1 B | USA |
 |
Quest Diagnostics Incorporated
DGX
|
1.46 B | $ 190.17 | -2.46 % | $ 21.1 B | USA |
 |
Exagen
XGN
|
40.6 M | $ 2.7 | -1.28 % | $ 58.2 M | USA |
 |
Invitae Corporation
NVTA
|
343 M | - | - | $ 21.2 M | USA |
 |
OpGen
OPGN
|
21.9 M | - | -16.95 % | $ 1.54 M | USA |